ArticleBMJ oncology2026
Bladder-sparing strategies for non-muscle-invasive bladder cancer after bacillus Calmette-Guérin failure: a systematic review.
Article in BMJ oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Non-muscle-invasive bladder cancer (NMIBC) is typically managed with transurethral resection and intravesical instillation therapy. For patients with high-risk NMIBC after failure of bacillus Calmette-Guérin (BCG) therapy, radical cystectomy and urinary diversion are the standard of care, which can be associated with a high morbidity and impaired quality of life. Developing efficacious bladder-sparing strategies is an unmet need for such patients. We conducted a systematic review of prospective interventional studies on NMIBC after BCG failure. Methods and analysis: We comprehensively searched the Cochrane Database, PubMed and ClinicalTrials.gov to identify prospective studies on NMIBC after BCG failure from their inception up to June 2025. Search results were summarised according to types of agents by focusing on efficacy. To assess the risk of bias, the Methodological Index for Non-Randomized Studies was used for single-arm studies, while the Risk of Bias 2.0 tool was applied to randomised controlled trials. Results: Of 2493 studies screened, 114 studies met the eligibility criteria, of which most were early-phase or single-arm trials. Types of agents or modalities used included immunotherapy and biological response modifiers, cytotoxic anticancer drugs, immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors, antibody-drug conjugates, radiotherapy and photodynamic therapy; of these, the former three accounted for more than 80% of the eligible trials. Among 37 published studies, complete response (CR) rates in patients with carcinoma in situ with or without papillary NMIBC ranged from 8% to 84%, and 12-month recurrence-free survival rates ranged from 20% to 86%. Interim reports of several ongoing trials using a novel intravesical drug delivery system of gemcitabine, gene therapy-based biological response modifiers with or without ICI, and a combination of ICI with anticancer agents demonstrated CR rates of 70% or higher. Conclusion: This systematic review demonstrated the promising efficacy of novel bladder-sparing strategies for NMIBC after BCG failure. This review is limited by the predominance of early-phase trials and a limited number of comparative studies, offering only limited guidance for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.